Australia markets closed

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
317.00+18.40 (+6.16%)
At close: 05:59PM BST
Full screen
Previous close298.60
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume96
Avg. volume36,818
Market cap18.481B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)-16.82
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at September 29, 2023

    Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a

  • GlobeNewswire

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related secu

  • GlobeNewswire

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

    Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 20,102 divided into 20,102 new shares with a nominal value of DKK 1 each. The i